Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Oct;4(5):865-86.
doi: 10.2147/tcrm.s3133.

Docetaxel in the treatment of squamous cell carcinoma of the head and neck

Alexander Rapidis  1 , Nicholas Sarlis, Jean-Louis Lefebvre, Merrill Kies
Affiliations

Docetaxel in the treatment of squamous cell carcinoma of the head and neck

Alexander Rapidis et al. Ther Clin Risk Manag. 2008 Oct.

Erratum in

  • Ther Clin Risk Manag. 2008 Dec;4(6):1381

Abstract

Squamous cell carcinoma of the head and neck (SCCHN) presents at a locally advanced (LA) stage in many patients. Chemotherapy has been successfully integrated into first-line treatment programs, either during or prior to radiotherapy (RT) - the cornerstone modality for local disease control of inoperable disease or when organ preservation is desired. Concomitant chemoradiotherapy (CCRT) provides an absolute survival benefit when compared with other types of locoregional therapy that exclude chemotherapy. Nonetheless, distant metastases still represent the most common cause of treatment failure. Consequently, adding induction chemotherapy (ICT) to definitive non-surgical local therapies with a curative intent has been vigorously explored in LA SCCHN. Recently, it has been shown that ICT using the combination of the taxane docetaxel with cisplatin-5-fluorouracil provides significant survival benefit over cisplatin-5-FU, when used before either definitive RT (TAX323 trial) or carboplatin-based CCRT (TAX324 trial). Docetaxel is also being investigated in metastatic or recurrent (M/R) disease, with promising initial results. It is very likely that the future management strategies of SCCHN will incorporate biologic agents as an add-on to docetaxel-containing schemas, administered either as ICT prior to CCRT in the LA setting or for the management of M/R disease.

Keywords: chemoradiotherapy; chemotherapy; docetaxel; head and neck carcinoma; induction; locally advanced; taxane.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Adelstein DJ, Leblanc M. Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer? J Clin Oncol. 2006;24:2624–8. - PubMed
    1. Adelstein DJ, Saxton JP, Lavertu P, et al. Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy. J Clin Oncol. 2002;20:1405–10. - PubMed
    1. Airoldi M, Cattel L, Marchionatti S, et al. Docetaxel and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. Am J Clin Oncol. 2003;26:378–81. - PubMed
    1. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16:1310–7. - PubMed
    1. Argiris A, Goldwasser A, Brockstein B, et al. Weekly docetaxel (D) and irinotecan (I) in patients (pts) with recurrence of metastatic head and neck cancer (HNC): a phase II trial of the Eastern Cooperative Oncology Group (ECOG) [abstract] J Clin Oncol. 2005;23(16S) Abstract 5528.